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Summary Fifty-one samples of non-malignant tissue from four mastectomies were analysed to assess oest-
rogen receptor (ER) and epidermal growth factor receptor (EGFR) status across the cancerous breast. No
significant relationship was found between the presence of EGFR and ER. Eighty-four per cent of these
samples were EGFR positive and 29% expressed both receptor types. EGFR and ER expression was not
affected by histological sub-group. In contrast, analysis of 44 primary cancers showed, in agreement with the
literature, a significant inverse relationship between the presence of ER and EGFR (Fisher's exact test
P<0.002). The difference between malignant and non-malignant tissue appeared to result from the prevalence
of co-expression of EGFR and ER in the non-malignant specimens. This suggests different regulation of
receptor expression in malignant and non-malignant tissue.
As a consequence of the increasing awareness of the role of
peptide growth factors in cellular growth, differentiation and
proliferation in normal tissue (Rowe & Friesen, 1984) and in
malignancy (Sporn & Roberts, 1985; Anonymous, 1986;
Lippman et al., 1986, 1987), attention is being focused on the
expression of their receptors in breast cancer. The receptor
for epidermal growth factor (EGF) is of particular interest
because of experimental evidence linking EGF with car-
cinogenesis (Stoschek & Lloyd, 1986).
In the past 4 years a great deal of evidence has been
obtained which suggests that an inverse relationship exists
between epidermal growth factor receptor (EGFR) and oest-
rogen receptor (ER) expression in primary breast carcinomas
in that co-expression of these two receptor types is rare, and
most tumours are either ER + ve or EGFR + ve (Perez et al.,
1984; Sainsbury et al., 1985a, b, 1987, 1988; Skoog et al.,
1986; Davidson et al., 1987; Wyss et al., 1987; Macias et al.,
1987; Nicholson et al., 1988a, 1989; Pekonen et al., 1988;
Travers et al., 1988; Cappelletti et al., 1988; Wrba et al.,
1988; Delarue et al., 1988). It has also been suggested that
the detection of EGFR in a primary breast tumour indicates
a poor prognosis (Sainsbury et al., 1987; Nicholson et al.,
1989). As the expression of EGFR is not limited to malig-
nant breast cells but has also been found in normal breast
tissue adjacent to primary tumours (Ozawa et al., 1988) and
in the normal breast cell line, HBL-100 (Fitzpatrick et al.,
1984), and furthermore since cultured cells from benign
breast fibroadenomas have been shown to respond to EGF in
vitro (Stokes et al., 1976), our investigation addresses the
incidence of EGFR in the non-malignant part of the
cancerous breast and its relationship with oestrogen receptors
(ER) and progesterone receptors (PgR).
Materials and methods
Breast tissue
Specimens were obtained from four breasts following mastec-
tomy for previously untreated primary breast cancer. Two
patients were premenopausal, both aged 39, and two were
post-menopausal, aged 74 and 77. Each breast was divided
into 16 equal sectors. From the centre of each sector tissue
was removed and divided into two equal halves, which were
placed respectively in liquid nitrogen for receptor assay and
buffered formalin for histological examination (for details see
Panahy et al., 1987). Two of the resulting 64 sectors were not
available, leaving 62 samples for receptor analysis.
Forty-four primary breast carcinomas were treated
similarly.
Reagents
Radioinert mouse epidermal growth factor (EGF) was
obtained from Sigma Chemical Co. (Poole, England). 251-
labelled EGF was produced in our laboratory using lodogen
iodination reagent (Pierce UK, Luton), and purified by G-50
Sephadex chromatography, to give '25I-EGF of specific
activity of approximately 400 Ci mmol-. All radioisotopes
were purchased from Amersham International plc, England.
Tissue storage andpreparation
Specimens were frozen in liquid nitrogen immediately after
surgical resection, and stored in liquid nitrogen. Samples
were ground in the presence of dry ice in a tissue grinder.
Following addition of 10ml g- tissue of 50 mM phosphate
buffer (pH 7.4) containing 1.5mM EDTA, 10% glycerol (all
from BDH Ltd, Poole, England), 10mM monothioglycerol
(Sigma), aprotinin (1 gLg ml- i; Sigma) and soybean trypsin
inhibitor (1 fig ml- i; BDH), further homogenisation was car-
ried out using a Polytron (Kinematica GmbH, Switzerland).
After centrifugation at 100,000 g for 1 h, at 4°C, the super-
natant was retained for soluble oestrogen receptor assays.
The particulate residue was resuspended in tris buffer
(pH 7.4) containing 50 mm sodium chloride and aprotinin
and soybean trypsin inhibitor, as above, and retained for
EGFR assay.
Protein estimation was carried out using the method of
Lowry et al. (1951).
EGF receptor (EGFR) assay
A radioligand binding assay was used to measure EGFR
concentrations following the method of Nicholson et al.
(1988b). Aliquots of the particulate fraction, representing a
crude membrane fraction, were incubated in duplicate with a
single concentration of '25I-EGF (final concentration 1 nM).
To measure non-specific binding, similar tubes were set up
which contained i2I-EGF together with a 100-fold excess of
unlabelled EGF (final concentration 100 nM). After a 2-h
incubation at 26°C the tubes were transferred to an ice-bath
and subsequently kept at 4°C. Ice-cold tris buffer (containing
0.1% w/v bovine serum albumin) was then added and the
suspension was centrifuged at 10,000 g for 5 min. The super-
natant was discarded and the pellet was washed and recent-
rifuged with a further aliquot of ice-cold tris buffer. This
second supernatant was discarded and the pellet was counted
in a gamma-counter (NE 1600, Thorn Nuclear Enterprises).
Rat liver and human placental membrane suspensions were
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used as positive controls. Intra-assay variation was less than
5% and inter-assay variation was 9%.
The detection limit for the assay (value significantly
different from zero) was 3 fmol mg ' protein and specific
binding was invariably greater than 25% of total binding.
Steroid hormone receptor radioligand binding assays
The single-saturating dose assay (King et al., 1979; Pud-
defoot et al., 1987) was used to measure soluble oestrogen
receptors. Briefly, this involved incubation of aliquots of
cytosol in the presence of 17 nM tritiated 17-beta oestradiol
(sp.act.llCi mmol-') for 18 h at 4°C, without or with a
100-fold excess of diethylstilboestrol, to determine total and
non-specific binding, from which a value for specific (recep-
tor) binding was obtained. Bound radioactivity was separated
by the dextran-coated charcoal method and counted by
liquid scintillation spectrophotometer. The detection limit for
this assay was 5 fmol mg-' protein.
A single-saturating dose assay also was used to determine
progesterone receptor concentrations. The method was as for
ER assay except that the radioligand used was tritiated pro-
gesterone (sp.act. 85 Ci mmol 1) at a final concentration of
28 nM.
A 100-fold excess of 19-norethindrone was used to estimate
non-specific binding and all tubes contained cortisol (final
concentration I x 10-6M) to eliminate binding to cortico-
steroid binding globulin. The detection limit for this assay
was 10 fmol mg-' protein.
Histopathology
Samples fixed in buffered formalin were processed to paraffin
in the usual way and 5lsm sections examined in haematox-
ylin and eosin preparations (Panahy et al., 1987).
Results
Non-malignant tissue
Sixty-two specimens from the four 16-sector mastectomies
were analysed. However, as malignant cells were found in 11
of these, only 51 histologically proven non-malignant speci-
mens were included in this group. Ofthese, 84% (43/51) were
EGFR positive and of the ER positive samples only 12%
(2/17) were EGFR negative. Figure I shows the concentra-
tions and distribution of ER and EGFR in the non-malig-
nant group. EGFR positive concentrations ranged from 3 to
39 fmol mg-' protein; ER positive from 5 to 134 fmol mg-'
protein. No significant relationship was found between the
presence of ER and EGFR in the non-malignant group using
either Fisher's exact test (P<0.30) or Kendall's rank correla-
tion (P<0.2).
The non-malignant samples could be divided, according to
the predominant tissue present, into three different histo-
logical sub-groups of normal/fat, fibrous/connective and
benign/fibrocystic tissue. Figure 2 shows their respective
receptor concentration ranges. No significant differences were
found between the means of the positive values in each
sub-group with respect to either ER concentrations or EGFR
concentrations, or when comparing receptor concentrations
between the four individual mastectomies (Table I).
Similarly, no significant differences were found between the
relative proportions of each receptor phenotype in a given
sub-group (Table II). Table II also includes data on mastec-
tomy samples with tumour infiltration. Furthermore, no sig-
nificant differences in receptor phenotype distributions were
found between samples taken from the two premenopausal
and the two post-menopausal patients, and no relationships
were found with respect to the anatomical segments from
which the samples were obtained in any of the individual
patients. PgR concentrations where positive ranged from 10
to 500fmolmg-' protein. No significant relationships were
found between PgR and either ER or EGFR expression.
Three samples of breast tissue were also obtained from one
patient undergoing reduction mammoplasty. Of these, all
were EGFR positive (4-14 fmol mg-' protein) and one was
also found to be positive for ER (30fmolmg-' protein).
Primary breast cancers
In contrast to the non-malignant group, of 44 primary breast
cancers analysed, 71% (32/44) could be classified as either
ER + /EGFR - or ER - /EGFR+ . Figure 3 shows the
receptor concentrations of ER and EGFR in this series of
tumour samples. EGFR positive concentrations ranged from
3 to 57 fmol mg-' protein; ER positive from 5 to
77fmolmg-' protein. A highly significant inverse relation-
ship was shown to exist between ER and EGFR expression
in the malignant group, so that in ER + ve primary cancers
EGFR were usually undetectable, and vice versa (Fishers's
exact test, P<0.002).
Figure 4 compares distribution of receptor phenotypes in
the non-malignant and malignant groups. Of the ER positive
non-malignant samples 88% (15/17) were EGFR positive
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Figure 1 Pooled data of receptor distribution for 51 non-malig-
nant samples. EGFR concentration measured by radioligand bin-
ding assay (y axis). ER concentration measured by radioligand
binding assay (x axis). Dashed lines indicate detection limits of
each assay. Points to the left of the vertical dashed line represent
samples in which ER concentrations were undetectable. Points
below the horizontal dashed line represent undetectable EGFR.
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Figure 2 Concentration ranges of ER and EGFR in histological
sub-groups of non-malignant cancerous breast samples. Solid
horizontal bars indicate the mean of the positive values. Dashed
lines indicate detection limits for radioligand binding assay for
each receptor.
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Table I Analysis ofdata from individual patients comprising the non-malignant
tissue group
Receptor concentration (fmolmg-' protein)
ER EGFR
Patient Range Mean±s.d. Median Range Mean±s.d. Median
P.D. 5-32 22.2±9 <5 3-21 6.2±4.7 4
C.S. 5-18 10.8±5 <5 3-23 7.5±5.7 5
M.P. 5-40 25.2±14 <5 3-39 12±11.41 6.5
C.G. 5-134 40.4±62 <5 3-9 6.2±2 5
Patients P.D. and C.S. were premenopausal and patients M.P. and C.G. were
post-menopausal.
Table II Distribution of receptor phenotypes in each histological
sub-group of non-malignant cancerous breast
Receptor phenotype
EGFR + / EGFR + / EGFR-/ EGFR-/
Histology ER- ER + ER- ER +
Normal/fat 10 (62.5) 4 (25) 2 (12.5) 0
Fibrous/ 5 (62.5) 2 (25) 1 (12.5) 0
connective
Benign/ 13 (49) 9 (33) 3 (11) 2 (7)
fibrocystic
Tumour 6 (55) 2 (18) 3 (27) 0
infiltration
Percentage ofsamples with each receptor phenotype for a particular
sub-group in parentheses.
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Figure 4 Comparison of receptor phenotype distribution in
tumour and non-malignant samples. Height of bars represents
percentage of total samples expressing a given phenotype.
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Figure 3 Pooled data showing receptor distribution in a series of
44 primary breast cancers. EGFR concentration measured by
radioligand binding assay (y axis). ER concentration measured by
radioligand binding assay (x axis). Dashed lines indicate detection
limits of each assay. Points to the left of the vertical dashed line
represent samples in which ER concentrations were undetectable.
Points below the horizontal dashed line represent undetectable
EGFR.
while only 17% (3/23) of the ER positive tumours also
expressed EGFR. In addition, whether ER + or ER -, the
proportion of EGFR + ve samples was greater in the non-
malignant group; 43/51 (84%) versus 15/44 (34%).
PgR concentrations where positive ranged from 10 to
526 fmol mg-' protein and no significant relationships were
found between PgR and either ER or EGFR in the tumour
group.
Comparison of tissue yields between non-malignant tissue
groups and the tumour group (Table III) indicates that the
latter shows relatively higher protein yields for both memb-
rane and cytosolic fractions.
Table III Comparison of tissue yields from the different histological
groups
Tissue yield
Membrane protein Cytosolic protein
Histological group per gram wet weight per gram wet weight
Non-malignant 2.1 ± 1.8 16.2 ± 8.0
Normal/fat 1.4 1.1 14.7 ± 7.4
Fibrous/connective 0.8 ± 1.0 10.4 ± 7.0
Benign/fibrocystic 2.8 ± 2.0 18.8 ± 7.8
Tumour infiltration 3.8 ± 3.2 28 ± 10
Primary tumours 3.7 2.4 26.1 ± 7.8
Samples in the non-malignant group were obtained from four
individual mastectomies. The primary tumours were taken from 44
individual patients.
Discussion
Our data represent the first systematic study of the relation-
ship between EGFR and ER in the cancerous breast after
excision of the primary cancer. EGFR is present in all types
of non-malignant tissue although its level of expression may
be relatively low compared with the top range previously
reported in primary breast tumours. Furthermore, the results
from the series of tumours analysed in this study agree with
previous work in demonstrating the absence of EGFR and
ER co-expression, and it is therefore extremely significant to
find that in the non-malignant group the two receptor types
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were found to co-exist in a significant proportion of speci-
mens analysed, irrespective of histological sub-group. This
finding is the more remarkable in view of the highly hetero-
geneous nature and the frequently low cellularity of non-
malignant breast tissue (Table III). The results suggest that
the inverse relationship between ER and EGFR which is
found in tumours may reflect an abnormal regulatory state
confined to the tumour itself. Travers et al. (1988) have also
analysed non-malignant breast tissue for the presence of
growth factor mRNA. Their results indicate that, while an
inverse relationship between ER-mRNA and EGFR-mRNA
could be found in malignant tumours, EGFR-mRNA was
always detectable in benign tumours and in four samples of
normal breast tissue, although at a low intensity. Our data
confirms and extends these findings to receptor protein exp-
ression in non-malignant tissue throughout the cancerous
breast.
One explanation for the differences observed between
tumour and non-malignant breast tissue with respect to ER
and EGFR could be that during the process of malignant
transformation tumour cells acquire the ability to synthesise
transforming growth factor alpha (TGF-alpha), a known
mitogen which acts via EGFR (Stoschek & Lloyd, 1986). It
might be argued that ifTGF-alpha is produced in tumours in
sufficiently high concentration (Dickson & Lippmann, 1986;
Bates et al., 1988) EGFR sites may be saturated and thus be
undetectable by radioligand binding assay, whereas in normal
tissue low levels of EGFR might be detectable. This argu-
ment would conflict with the evidence of Travers et al.
(1988), who showed that mRNA for ER and EGFR were not
found to co-exist to any significant extent in primary breast
carcinomas. It is well established that in addition to stim-
ulating EGFR mRNA synthesis, EGF or TGF-alpha can
cause 'down-regulation' of EGFR by receptor internalisation
and degradation (Carpenter, 1987; Schlessinger, 1988). It
might be possible, therefore, that long-term exposure to
TGF-alpha leads to suppression of EGFR mRNA synthesis.
Sainsbury et al. (1987) and Nicholson et al. (1988b, 1989)
have suggested a clinically significant cut-off value for EGFR
in tumours of 10fmol mg-' protein. Using this limit they
have shown that the presence of an EGFR positive tumour
indicates a worse prognosis, in terms of relapse-free survival,
compared with EGFR negative tumours. However, it is clear
from our data that the observations of a tumour with EGFR
+ ve/ ER -ve phenotype may not necessarily be abnormal as
55% of our non-malignant samples expressed this phenotype
and only one primary tumour had an EGFR concentration
above the range of concentrations found in the non-malig-
nant group. Ozawa et al. (1988) have suggested that EGF
binding is significantly higher in breast tumours compared to
normal adjacent tissue, although 50% of their tumours gave
EGF binding levels within the range of the normal samples.
It is likely therefore that the significance of EGFR as a
prognostic indicator is the result of a number of factors.
There may be an advantage conferred to the EGFR nagative
group by the presence of a functional ER system, but a
disadvantage associated with over-expression of EGFR aris-
ing from gene amplification (Ro et al., 1988) or high trans-
cription rates (Davidson et al., 1987) which are not subject to
normal regulatory mechanisms.
An alternative explanation for the differences between non-
malignant tissue and primary breast cancers might be that
the tumours represent clonal selection of cells which express
only one or other of these receptor types. Wrba et al. (1988)
have suggested that the inverse relationship between EGFR
and ER status may indicate the existence of two different
sub-populations on the basis of differentiation and growth
control. One group may represent those tumours which are
primarily regulated by EGF and EGF-related molecules. The
other group may consist of tumours predominantly respon-
sive to steroid hormones. Meanwhile, as we have shown in
non-malignant tissue both EGFR and ER can more often be
detected in the same tissue specimen implying that normally
both receptor types are expressed.
We conclude therefore, from our data on non-malignant
tissue, that in the normal breast both ER and EGFR co-exist
to maintain regulated cell growth, and that this system
becomes uncoupled during malignant transformation.
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